– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure,…
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic…
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly improved patient quality of life and reduced disease…
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target…
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET February 22, 2025 02:20 ET | Source: Teva…
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) --…
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's…
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
